R. V. Vollenhoven

发表

Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort

K. Chatzidionysiou, R. Vollenhoven, R. V. Vollenhoven, 2013, Scandinavian journal of rheumatology.

Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study.

I. Bruce, D. Gladman, M. Urowitz, 2007, Arthritis and rheumatism.

Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.

I. Bruce, D. Gladman, M. Urowitz, 2008, Arthritis and rheumatism.

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

C. Gordon, M. Petri, M. Ward, 2009, Annals of the rheumatic diseases.

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus

J. Ioannidis, C. Gordon, D. Isenberg, 2008, Annals of the rheumatic diseases.

Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus

D. Gladman, M. Urowitz, P. Fortin, 2010, Arthritis care & research.

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs

J. Ioannidis, I. Bruce, M. van Buchem, 2010, Annals of the rheumatic diseases.

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

M. Urowitz, R. V. van Vollenhoven, C. Molta, 2016, Lupus.

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

R. Levy, M. Petri, S. Navarra, 2013, Lupus.

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort

I. Bruce, D. Gladman, M. Urowitz, 2016, Lupus Science & Medicine.

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

J. Ioannidis, C. Gordon, D. Isenberg, 2007, Annals of the rheumatic diseases.

Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus

I. Bruce, D. Gladman, E. Ginzler, 2009, Annals of the rheumatic diseases.

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

J. Buyon, T. Dörner, J. Merrill, 2015, Annals of the rheumatic diseases.

Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study.

I. Bruce, D. Gladman, M. Urowitz, 2008, Arthritis and rheumatism.

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients

I. Bruce, D. Gladman, E. Ginzler, 2017, Lupus.

VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics.

K. Richards, N. Teng, R. V. van Vollenhoven, 1999, The Journal of rheumatology.

Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity

D. Gladman, L. Magder, M. Urowitz, 2011, Lupus.

SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus

I. Bruce, D. Gladman, M. Urowitz, 2011, Annals of the rheumatic diseases.

Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study.

I. Bruce, D. Gladman, E. Ginzler, 2008, Arthritis and rheumatism.

Psychosocial correlates of morbidity in women with systemic lupus erythematosus.

R. E. Lambert, M. Ward, C. Neuwelt, 1999, Journal of Rheumatology.

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

A. Doria, A. Schwarting, W. Stohl, 2018, Arthritis & rheumatology.

Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.

D. Furst, P. Emery, X. Mariette, 2016, Annals of the rheumatic diseases.

Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus

D. Gladman, C. Gordon, D. Isenberg, 2010, Arthritis care & research.

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

I. Bruce, D. Gladman, M. Urowitz, 2012, Arthritis care & research.

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients

I. Bruce, D. Gladman, E. Ginzler, 2017, Arthritis care & research.

DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184

E. Hachulla, R. V. van Vollenhoven, D. Staumont-Sallé, 2015, Lupus.

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus

M. Olesińska, M. Mosca, G. Pokorny, 2010, Lupus.

S. Pettersson, S. Bergman, J. Frostegård, 2013, Lupus.

Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports

L. Jönsson, C. Bexelius, P. Skare, 2013, Lupus.

Limitations of current treatments for systemic lupus erythematosus: a patient and physician survey

V. Strand, C. Gălăţeanu, E. Nikaï, 2013, Lupus.

Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL

I. Gunnarsson, E. Svenungsson, F. Wermeling, 2018, Lupus.

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus

M. Genovese, R. V. van Vollenhoven, J. McGuire, 1999, Lupus.

of patients with systemic lupus erythematosus Disease activity and damage accrual during the early disease course in a multinational inception cohort

M. Olesińska, M. Mosca, G. Pokorny, 2010 .